Reuters
Fri Nov 20 2020
An ampule of Gilead Sciences COVID-19 antiviral remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Po
LONDON:Gilead's drug remdesivir is not recommended for patients hospitalised with COVID-19, regardless of how ill they are, as there is no evidence it improves survival or reduces the need for ventilation, a World Health Organization panel said on Friday.
"The ... panel found a lack of evidence that remdesivir improved outcomes that matter to patients such as reduced mortality, need for mechanical ventilation, time to clinical improvement, and others," the guideline said.
The advice is another setback for the drug, which grabbed worldwide attention as a potentially effective treatment for COVID-19 in the summer after early trials showed some promise.
At the end of October, Gilead cut its 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir.
The antiviral is one of only two medicines currently authorised to treat COVID-19 patients across the world, but a large WHO-led trial known as the Solidarity Trial showed last month that it had little or no effect on 28-day mortality or length of hospital stays for COVID-19 patients.
The medication was one of the drugs used to treat U.S. President Donald Trump's coronavirus infection, and had been shown in previous studies to have cut time to recovery. It is authorised or approved for use as a COVID-19 treatment in more than 50 countries.
Gilead has questioned the Solidarity Trial's results.
"Veklury is recognised as a standard of care for the treatment of hospitalised patients with COVID-19 in guidelines from numerous credible national organisations," Gilead said in a statement, referring to the drug's brand name.
"We are disappointed the WHO guidelines appear to ignore this evidence at a time when cases are dramatically increasing around the world and doctors are relying on Veklury as the first and only approved antiviral treatment for patients with COVID-19."
The WHO's Guideline Development Group (GDG) panel said its recommendation was based on an evidence review that included data from four international randomised trials involving more than 7,000 patients hospitalised with COVID-19.
After reviewing the evidence, the panel said, it concluded that remdesivir, which has to be given intravenously and is therefore costly and complex to administer, has no meaningful effect on death rates or other important outcomes for patients.
"Especially given the costs and resource implications associated with remdesivir ...the panel felt the responsibility should be on demonstrating evidence of efficacy, which is not established by the currently available data," it added.
The latest WHO advice comes after one of the world's top bodies representing intensive care doctors said the antiviral should not be used for COVID-19 patients in critical care wards.
The WHO's recommendation, which is not binding, is part of its so-called "living guidelines" project, designed to offer guidance for doctors to help them make clinical decisions about patients in fast-moving situations such as the COVID-19 pandemic. The guidelines can be updated and reviewed as new evidence and information emerges.
The panel said, however, that it supported continued enrolment into clinical trials evaluating remdesivir in patients with COVID-19, which it said should "provide higher certainty of evidence for specific groups of patients".
The recommendation may raise further questions about whether the European Union will need the 500,000 courses of the antiviral worth 1 billion euros it ordered last month.Enable GingerCannot connect to Ginger Check your internet connection
or reload the browserDisable in this text fieldEditEdit in GingerEdit in Ginger
Nahas skuter elektrik meningkat di Jepun selepas peraturan dilonggar
Dalam tempoh enam bulan sejak Julai lepas, 85 nahas lalu lintas melibatkan skuter elektrik dicatatkan dan mengakibatkan 86 kecederaan.
Mohamed Khaled tiba di Indonesia untuk lawatan rasmi, dijadual bertemu Prabowo
Menteri Pertahanan tiba di Jakarta pada Ahad untuk lawatan kerja rasmi sulung beliau ke Indonesia sejak memegang jawatan itu.
'Tersentuh tengok golongan OKU penglihatan tunai umrah’ - Mohd Na’im
"Moga terkabul segala hajat sahabat-sahabat OKU penglihatan menunaikan ibadat umrah dan ziarah."
PM Anwar yakin terhadap IsDB dalam tangani ketidaksamaan, marginalisasi umat Islam
Bank itu mempunyai peranan untuk menangani isu ketidakadilan, ketidaksamaan dan marginalisasi terutamanya dalam kalangan umat Islam.
Harumanis antara tarikan utama Agrofiesta 2024
Mangga harumanis dan produk makanan berasaskan mangga antara tarikan utama pada penganjuran Agrofiesta 2024.
NIOSH sedia beri khidmat nasihat depani cabaran perubahan iklim
NIOSH bersedia memberikan khidmat nasihat serta rundingan bagi membantu kerajaan, majikan dan pekerja menghadapi cabaran berkaitan perubahan iklim.
Malaysia negara pertama terima visa haji
Malaysia menjadi negara pertama yang menerima pengeluaran visa haji daripada Kementerian Haji dan Umrah Arab Saudi bagi jemaah musim haji 1445H/2024.
Menteri Indonesia bincang isu pekerja migran dengan rakan sejawat dari Malaysia
Fauziyah harap Steven akan membawa penambahbaikan kepada dasar berkaitan tenaga kerja Indonesia.
Pahang peruntuk RM1.5 juta bantuan tunai bakal jemaah haji
Sebanyak 1,588 jemaah haji Pahang menerima sumbangan 'duit poket' berjumlah RM750 seorang bagi membantu meringankan beban bakal haji dalam melakukan persiapan melaksanakan rukun Islam kelima itu.
PRK Kuala Kubu Baharu: Pengundi jangan mudah percaya taktik fitnah - Ramanan
Ramanan berkata pengundi perlu lebih berhati-hati, dan sentiasa menyemak fakta apabila mendengar kempen politik yang dilakukan pihak lawan.
Kelaparan akut jejaskan 281.6 juta orang tahun lepas - PBB
Tahap bahaya kelaparan akut menjejaskan 281.6 juta orang tahun lepas, tahun kelima berturut-turut bahawa ketakjaminan makanan semakin memburuk.
Hamilton optimis kedudukan lebih baik di GP China
Lewis Hamilton melihat potensi kedudukan yang lebih baik dalam saingan Grand Prix yang kembali ke China buat pertama kali dalam tempoh lima tahun, hujung minggu ini.
'Selfish!' - Fasha Sandha sedih raya di Perlis tak jadi gara-gara dijangkiti COVID-19
Fasha berkata dia mula melakukan pemeriksaan COVID-19 selepas berasa tidak sihat badan dan mengalami bersin tidak henti sejak Raya pertama.
Kes COVID-19 catat penurunan ketara pada ME 14/2024 - KKM
Jumlah kes COVID-19 menurun 97.1 peratus kepada 493 kes pada Minggu Epidemiologi ke-14 (ME 14/2024) iaitu bagi tempoh 31 Mac hingga 6 April lepas berbanding 17,256 kes pada ME 1/2024.
China jadikan pengalaman pencegahan COVID-19 untuk hadapi pandemik masa depan
China akan menjadikan pengalaman dalam pencegahan dan kawalan COVID-19 untuk membuat persediaan yang lebih proaktif untuk menghadapi pandemik masa depan seperti "Penyakit X".
Negara berdepan ketirisan subsidi diesel serius - Amir Hamzah
Negara kini sedang berdepan isu ketirisan subsidi diesel yang serius dan wujud kemungkinan terdapat pihak yang tidak layak masih menikmati subsidi itu, kata Menteri Kewangan II Datuk Seri Amir Hamzah.
Kematian akibat kemalangan jalan raya lebih tinggi daripada COVID-19 - Anthony Loke
PDRM akan mengeluarkan data mengenai kemalangan jalan raya pada setiap hari, bukan setahun sekali seperti diamalkan sebelum ini.
Ismail Sabri ziarah lapan beradik yatim piatu akibat COVID-19
Ismail Sabri tiba kira-kira jam 2 petang di kediaman lapan beradik itu di Taman Adenium, Bukit Beruntung pada Selasa.
Teori konspirasi 'Penyakit X'
Ahli teori konspirasi AS sekali lagi membuat 'keuntungan' selepas PBB memberi amaran tentang wabak lebih berbahaya iaitu 'Penyakit X'.
Reformasi dasar, kukuhkan perlindungan, produktiviti pekerja tidak formal
Reformasi dasar perlu dilakukan dalam usaha meningkatkan perlindungan dan produktiviti pekerja tidak formal di Malaysia.